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Abstract 
Background: Dynamic changes in glycaemia predominate peri-operatively in patients with 
type 2 diabetes mellitus (T2DM) undergoing metabolic surgery. There is a lack of consensus 
and clear guidance on effective glycaemic management of such patients. The aim of this 
study was to design, pilot and implement a proforma to improve consistency of glycaemic 
management, and clarity of communication with healthcare professionals following 
metabolic surgery in patients with T2DM, thereby reducing unnecessary Diabetes Specialist 
Nurse (DSN) referrals. 
Methods: A proforma was designed and piloted for 12-months to guide healthcare 
professionals on managing glycaemic therapies for T2DM patients undergoing metabolic 
surgery. Glycaemic control (HbA1C) and glycaemic therapies were reviewed 3-weeks pre-
operatively and a proforma was completed accordingly.  
Results: Of the patients with T2DM (n=34) who underwent metabolic surgery prior to the 
new proforma being implemented, 71% (n=24) had a DSN referral. Half of these referrals 
were deemed unnecessary by the DSNs. Of the patients with T2DM (n=33) who underwent 
metabolic surgery following implementation of the proforma, 21% (n=7) had a DSN referral. 
Only 10% of these were deemed unnecessary. Despite the reduced DSN input, no diabetes 
related complications were reported. 
Conclusion: Implementation of our proforma effectively halved the proportion of patients 
with T2DM requiring a DSN referral. Additionally, there was a 40% absolute reduction in the 
proportion of unnecessary DSN referrals. The proforma improved clarity of communication 
and guidance for healthcare professionals in the glycaemic management of patients. This also 
facilitated improved work-efficiency and resource allocation.  
Keywords: Type 2 Diabetes Mellitus; Metabolic surgery; Glycaemic control, Sleeve 
Gastrectomy 
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Introduction  
Over recent decades, metabolic surgery has risen to prominence globally as an effective and 
durable therapeutic option for patients with morbid obesity [1]. The effectiveness and utility 
of metabolic surgery is manifest primarily in the resultant weight-loss. Importantly however, 
it is well-established through much literature, including meta-analyses on many thousands of 
patients who have undergone metabolic surgery, that this therapeutic option is an excellent 
choice for patients with weight-related conditions that are reversible with weight-loss, such as 
Obstructive Sleep Apnoea (OSA) and Type 2 Diabetes Mellitus (T2DM). In some of the 
largest meta-analyses published to date, it was demonstrated that in those patients with OSA, 
resolution of this condition occurs in 86% of patients following metabolic surgery [2], and an 
equivalent proportion of those with T2DM experience substantial improvement in glycaemic 
control [3]. Furthermore, a large proportion of patients who undergo metabolic surgery in the 
UK (25% of women and 45% of men) have an established diagnosis of T2DM at the time of 
their surgery (data from the UK National Bariatric Surgery Registry) [4]. 
 
Improvements in glycaemic control in patients with T2DM who undergo metabolic surgery 
often occur quite rapidly following the procedure, and usually precede any reduction in 
weight [5]. The magnitude of glycaemic effects following metabolic surgery is procedure-
specific, with those that increase the rapidity of nutrient transit into the distal ileum 
(including gastric bypass procedures, and to a lesser degree sleeve gastrectomy) having the 
greatest effect on glycaemia [6-7]. Whilst the mechanisms that mediate improvements in 
glycaemia in patients with T2DM following metabolic surgery are incompletely understood, 
the ‘hind-gut hypothesis’ (faster post-prandial release of incretin hormones that include PYY 
and GLP1) is widely accepted as an important contributor [8-13]. Another important mediator 
may simply relate to reduced caloric (including glycaemic) intake in patients following 
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metabolic surgery, and the reduced need for glycaemic therapies. Whatever the actual 
mechanisms of glycaemic improvement however, it is important that glycaemic therapies 
(including oral and injectable options such as insulin) are adjusted appropriately within the 
metabolic surgical peri-operative period, to pre-empt the expected dynamic improvements in 
post-operative glycaemia, and avoid wide fluxes of glycaemia (including hypoglycaemia) 
[14-15]. 
 
Unfortunately, there is a general lack of consensus regarding correct adjustments to 
glycaemic therapies for T2DM in the metabolic surgical peri-operative period. Furthermore, 
clear guidelines from esteemed societies on this topic are lacking, with a dearth of evidence 
from the literature within this field [15]. Direct anecdotal feedback from the DSN’s who are 
involved in metabolic surgical peri-operative glycaemic management of patients with T2DM 
in our own Tier 4 obesity service, revealed inconsistent management practices amongst ward-
based health-care specialists, and frequent unnecessary DSN referrals, thereby compromising 
both work-efficiency and ultimately optimal patient care. We identified a clear need for 
development and implementation of local guidance, to unify and improve glycaemic 
management of patients with T2DM in the metabolic surgical peri-operative period. This 
provided a rationale for our study. 
 
Our aim was to design and implement our own proforma to improve consistency of 
glycaemic management, and clarity of communication with ward-based teams in the peri-
operative period following metabolic surgery in patients with T2DM. Through such a 
strategy, we also aimed to reduce and limit the number of unnecessary referrals to our DSN 
team. We reasoned that successful implementation of our proforma would improve both 
understanding and confidence in effective glycaemic management in the metabolic surgical 
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peri-operative period. This in turn would reduce the need for DSN input. In this way, the 
number of DSN referrals (total and unnecessary) was a barometer of the effectiveness of our 
implemented ward-based proforma, and was used as the main outcome variable for our study.  
 
Methods 
Research environment: Within the UK, the NHS Commissioning Board has published 
guidance on clinical commissioning of obesity management, based on a four tier model. This 
includes guidance on complex and specialized obesity surgery (by definition, tier 4) 
[16]. Regional weight management services are provided based on local needs and priorities. 
Whilst definitions vary locally, the obesity pathway consists of 4 four defined tiers: tier 1 
covers universal public health-based services; tier 2 covers lifestyle management typically 
administered in a primary-care based setting; tier 3 covers a multi-disciplinary specialist 
team-based approach, typically administered in a hospital setting, and; tier 4 covers bariatric 
surgery [17]. Whilst tier 2 services are usually commissioned by local authorities, tier 3 
services are usually commissioned by either local authorities or clinical commissioning 
groups. Tier 4 services are commissioned currently by NHS England. Prior to referral to a tier 
4 service for surgical assessment, all patients need to have attended and complied with a local 
tier 3-based weight-management service for a minimum of 6 months [18].  
 
Outcome variable: The main outcome variable was the proportion of patients with T2DM 
undergoing metabolic surgery, for whom a DSN referral was requested by the ward-based 
team. DSN referral rate was used as a measure of confidence within the ward-based team in 
the glycaemic management of such patients. In addition, the proportion of DSN referrals that 
were deemed unnecessary by the reviewing DSN was also assessed. The definition of 
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‘unnecessary’ was that in the view of the reviewing DSN, the glycaemic issue being referred 
could and should have been managed easily by the ward-based team. Examples included: 
i) No current or predicted problems with either hypoglycaemia or hyperglycaemia 
(blood glucose >15) in the peri-operative period;  
ii) Advice about standard NICE-based glycaemic therapy alterations such as the need to 
discontinue Metformin in the peri-operative period; 
iii) No need for any changes in current glycaemic therapies.  
 
Baseline assessment of DSN referrals: Prior to development and implementation of our new 
proforma, baseline data were collected on DSN referrals during the peri-operative period for 
patients with T2DM undergoing metabolic surgery in our Tier 3 and Tier 4 Obesity service 
within a tertiary care setting. The duration of data collection for the baseline assessment was 
a 12-month period, between October 2015 and October 2016. During this period, there were 
no local guidelines in place for ward-based staff managing such patients. 
 
Proforma development: Prior to commencement of the study, a new proforma was developed 
by our Tier 3 and Tier 4 Obesity team. This proforma was designed for use by ward-based 
healthcare professional staff who are involved in the peri-operative management of patients 
undergoing metabolic surgery in our Tier 3 and Tier 4 Obesity service. Clarity of 
communication and improved consistency and uniformity of peri-operative glycaemic 
management were key strategies in the design of the proforma. The proforma provided clear 
instructions on any modifications required for glycaemic therapies in patients with T2DM, 
with each class of glycaemic therapy listed. This included guidance on continuation, 
discontinuation and suggested dosage changes for specific glycaemic therapies. For ease of 
use, the proforma was designed to fit on one side of A4 paper, and is shown in figure 1. 
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Existing NICE guidance and evidence-base from the current literature for each glycaemic 
therapy was utilized in the process of proforma development [19].  
 
Proforma-based assessment of DSN referrals: Following successful design of the proforma, 
the main pilot study for its implementation had a duration of 12-months between November 
2016 and November 2017. As with the baseline assessment, data were collected on DSN 
referrals during the peri-operative period for patients with T2DM undergoing metabolic 
surgery at our tertiary centre, but this time with the developed proforma in place. To ensure 
adequate usage of the proforma, a copy was placed in the medical notes of each patient with 
T2DM who was due to have metabolic surgery at our tertiary centre during this period. In the 
immediate post-operative period, each patient was reviewed by an obesity-specialist Dietitian 
and Nurse within our Tier 4 team, who also reiterated correct usage of our proforma for 
glycaemic management by the ward-based staff. In addition to this, current glycaemic control 
(HbA1C) and glycaemic therapies were reviewed 3-weeks pre-operatively by the Tier 4 
obesity team in the pre-surgical group clinic setting. Finally, a letter was sent out to each 
patient with T2DM (and their GP) at 2-weeks prior to their metabolic surgery, outlining 
relevant instructions for their glycaemic therapies (based on the guidance in our proforma) in 
the peri-operative period for their upcoming metabolic surgery. Through this process, 
awareness of the details in our proforma was maximized for the patient, their GP and the 
ward-based staff. 
 
Post-operative management: Although not directly assessed during this pilot study, our 
proforma was also utilized for post-operative glycaemic management by Dietitians and 
Nurses within our Tier 4 obesity team during the study. Each patient was reviewed by a 
dedicated Nurse and Dietitian within our Tier 4 team at 7-10 days postoperatively. At this 
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routine appointment, our proforma was also used as a guide for ongoing post-operative 
glycaemic management. Patients on insulin were encouraged to undertake regular blood 
glucose monitoring at home and to contact the team if necessary. Support from our DSN 
team, and Consultant Diabetologist was available where required, thereby maintaining 
excellent glycaemic management throughout the patient journey. 
 
Results  
Baseline assessment of DSN referrals: During the 12-month period of assessment prior to 
implementation of our new proforma, there were 34 patients with T2DM who underwent 
metabolic surgery. Of these 34 patients, the majority (n=24; 71%) had had a referral to the 
DSN by the ward-based staff during the metabolic surgical peri-operative period. Half of 
these referrals were deemed unnecessary by the reviewing DSN.  
 
Proforma-based assessment of DSN referrals: During the 12-month period of assessment 
following design and implementation of our new proforma, there were 33 patients with 
T2DM who underwent metabolic surgery. Of these 33 patients, a minority (n=7, 21%) had 
had a referral to the DSN by the ward-based staff during the metabolic surgical peri-operative 
period. Only 10% of these referrals were deemed unnecessary by the reviewing DSN. In the 
12-month period when our new proforma was piloted, there were 17 fewer DSN referrals 
than during the 12-month period of assessment prior to our proforma being implemented 
(based on proportions of patients having DSN referral for each of the study periods). There 
was also a 40% absolute reduction in the proportion of DSN referrals deemed unnecessary 
following implementation of our proforma. 
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Discussion  
Our data demonstrates a 50% reduction in the proportion of patients with T2DM who had a 
DSN referral from ward-based staff, during the metabolic surgical peri-operative period 
within the Tier 4 setting at our tertiary centre, following successful design and 
implementation of a proforma for management of glycaemia in such patients. There was a 
substantial absolute reduction (40%) in the proportion of DSN referrals that were deemed 
unnecessary by the reviewing DSN. To our knowledge, this is the first Tier 4-based centre 
report on DSN referral data following successful design and implementation of a bespoke 
proforma for metabolic surgical peri-operative glycaemic management of T2DM. Our data 
demonstrate that over the course of a year, there were 17 fewer DSN referrals requested with 
use of our proforma compared with its non-use. Our data show that implementation of a 
simple management strategy can have quite profound implications for work efficiency, 
resource utilization, and ultimately optimizing patient-care. 
 
Although not directly measured in our study, we hypothesize that the substantial reduction of 
both total and unnecessary DSN referrals following implementation of our proforma was 
reflective of improved clarity of communication of peri-operative glycaemic management 
strategy with ward-based teams. Improved uniformity of glycaemic management through use 
of the proforma would have further strengthened confidence amongst ward-based staff in 
peri-operative management of glycaemia in T2DM, thereby reducing the need for DSN 
referral. Our strategy for successful implementation of our proforma also included discussion 
of details related to peri-operative glycaemic management with each patient prior to their 
surgical date within group-based clinics (based on details within the proforma), and 
communication of such details with the each patient’s GP. These additional communication 
streams further optimized clarity, uniformity and consistency of communication regarding 
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peri-operative glycaemic management. Direct implications of the successful implementation 
of our proforma include improved standard and continuity of patient care and safety.        
 
The NHS is a complex system, with many examples of inefficiency [20-21]. Whilst causation 
for such inefficiency is usually multifactorial, procedure and protocol are often key. Work-
based practices often become entrenched, and typically vary between each locality. An 
example of NHS inefficiency is that of work-based practices, specifically regarding referrals 
of patients to specialty-based teams, when such a referral is not needed. Improving ward-staff 
knowledge and having clear treatment guidelines may overcome this problem. Given the 
current pressures on the NHS, with increasing hospital admissions, ageing population and 
increased prevalence of chronic disease (including obesity and T2DM), combined with 
limited resources, it is important to explore how work-based efficiency can be improved, and 
to implement measures to effect such a change. Our data provide an excellent example of 
how relatively simple measures (that of implementing simple, easy to use and inexpensive 
standard and logical guidance for metabolic surgical, peri-operative glycaemic management 
for patients with T2DM on one side of A4 paper, combined with multi-level and unified 
communication streams) can have quite profound implications for work-based efficiency and 
resource allocation. Through substantial reduction in DSN referrals, our DSN time was freed 
up for more appropriate allocation to other patients with Diabetes Mellitus who would benefit 
from DSN input. In short, work-based efficiency and effectiveness was substantially 
improved through successful implementation of our proforma. 
 
An important limitation of our study was that that our proforma was not always made clearly 
visible in the patient’s admission notes whilst on the ward in the peri-operative period. One 
possible reason for this could be limited awareness of our pilot study amongst ward-based 
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staff. Increased training of ward-based staff prior to future implementation of the proforma is 
likely to mitigate this problem. A further limitation was that no assessment of peri-operative 
glycaemic control or length of hospital stay was performed during our study, the main 
outcome variable being DSN referral rate. Future studies should focus on the effects of 
proforma implementation on glycaemic control and variability and length of hospital stay in 
addition to DSN referral rates. Finally, future studies should also focus on the patient 
perspective, to strengthen our hypothesis that utilization of our proforma improves the patient 
peri-operative experience and journey. A small sample size is another limitation of this study. 
Future studies concentrating on a larger sample size and other centers’ experiences in using 
the proforma, will assist in the generalisability of our findings. 
 
To summarize, we demonstrate for the first time, that successful design and implementation 
of a bespoke guideline for glycaemic management of T2DM in the metabolic surgical peri-
operative period within a Tier 4 setting is feasible. Such a simple and inexpensive strategy 
results in substantial reductions in both total and unnecessary DSN referrals, and has quite 
profound implications for improved work-based efficiency and resource allocation. A likely 
mediator of such beneficial effects is the effect of our proforma as an expedient for improved 
clarity, consistency and uniformity of communication streams to all relevant healthcare 
professionals, and the patient. We recommend that our proforma is adopted and embraced by 
other Tier 4 centres, and that further research into its clinical utility is conducted. Scalability 
of our proforma would maximize potential for work-based efficiency throughout the NHS 
and other healthcare organizations involved with metabolic surgery, and result in improved 
patient care, experience and safety.    
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